Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus

Synapse

Volumn 69, Issue 10, 2015, Pages 484-496

  Fernández Fernández, Diego ^a   Rosenbrock, Holger ^a   Kroker, Katja S ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Alzheimer's disease; BAY 41 8543; Hippocampus; PDE2A; PDE9A

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; BAY 73 6691; CALCIUM; CALCIUM CHANNEL L TYPE; CYCLIC AMP; CYCLIC GMP; FORSKOLIN; GLUTAMIC ACID; PF 999; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2A; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; 1H-(1,2,4)OXADIAZOLO(4,3-A)QUINOXALIN-1-ONE; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; ADENOSINE; AMINO ACID RECEPTOR BLOCKING AGENT; CADMIUM CHLORIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; OXADIAZOLE DERIVATIVE; PDE2A PROTEIN, RAT; PYRIMIDINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; EXCITATORY POSTSYNAPTIC POTENTIAL; EXTRACELLULAR CALCIUM; FACILITATION; HIPPOCAMPAL CA1 REGION; IC50; MALE; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NERVE ENDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIRED PULSE FACILITATION; PRESYNAPTIC SHORT TERM PLASTICITY; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; RAT; SYNAPTIC TRANSMISSION; ANIMAL; CYTOLOGY; DRUG EFFECTS; LONG TERM POTENTIATION; METABOLISM; NERVE CELL; PHYSIOLOGY; WISTAR RAT;

ADENOSINE; ANIMALS; CA1 REGION, HIPPOCAMPAL; CADMIUM CHLORIDE; COLFORSIN; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; LONG-TERM POTENTIATION; MALE; MORPHOLINES; NEURONS; OXADIAZOLES; PRESYNAPTIC TERMINALS; PYRIMIDINES; QUINOXALINES; RATS; RATS, WISTAR;

EID: 84939542083     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21840     Document Type: Article

References (62)

1. Bales KR, Plath N, Svenstrup N, Menniti FS. 2010. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer's Disease. In: Dominguez C, editor. Neurodegenerative diseases. Heidelberg: Springer. p 57-90.
2. Bender AT, Beavo JA. 2006. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58:488-520.
3. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G. 2004. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081-1092.
4. Bollen E, Prickaerts J. 2012. Phosphodiesterases in neurodegenerative disorders. IUBMB Life 64:965-970.
5. Boyken J, Grønborg M, Riedel D, Urlaub H, Jahn R, Chua JJ. 2013. Molecular profiling of synaptic vesicle docking sites reveals novel proteins but few differences between glutamatergic and GABAergic synapses. Neuron 78:285-297.
6. Chavez-Noriega LE, Stevens CF. 1992. Modulation of synaptic efficacy in field CA1 of the rat hippocampus by forskolin. Brain Res 574:85-92.
7. Clark KA, Randall AD, Collingridge GL. 1994. A comparison of paired-pulse facilitation of AMPA and NMDA receptor-mediated excitatory postsynaptic currents in the hippocampus. Exp Brain Res 101:272-278.
8. Constals A, Penn AC, Compans B, Toulmé E, Phillipat A, Marais S, Retailleau N, Hafner AS, Coussen F, Hosy E, Choquet D. 2015. Glutamate-induced AMPA receptor desensitization increases their mobility and modulates short-term plasticity through unbinding from Stargazin. Neuron 85:787-803.
9. Conti M, Beavo J. 2007. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
10. Davare MA, Avdonin V, Hall DD, Peden EM, Burette A, Weinberg RJ, Horne MC, Hoshi T, Hell JW. 2001. A beta2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav1.2. Science 293:98-101.
11. Debanne D, Guérineau NC, Gähwiler BH, Thompson SM. 1996. Paired-pulse facilitation and depression at unitary synapses in rat hippocampus: Quantal fluctuation affects subsequent release. J Physiol 491:163-176.
12. Dias RB, Rombo DM, Ribeiro JA, Henley JM, Sebastião AM. 2013. Adenosine: Setting the stage for plasticity. Trends Neurosci 36:248-257.
13. Domek-Lopacińska K, Strosznajder JB. 2008. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 1216:68-77.
14. Dunwiddie TV, Haas HL. 1985. Adenosine increases synaptic facilitation in the in vitro rat hippocampus: Evidence for a presynaptic site of action. J Physiol 369:365-377.
15. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. 1998. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564.
16. Gomez L, Breitenbucher JG. 2013. PDE2 inhibition: Potential for the treatment of cognitive disorders. Bioorg Med Chem Lett 23:6522-6527.
17. Heckman PR, Wouters C, Prickaerts J. 2015. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer&s disease: a translational overview. Curr Pharm Des 21:317-331.
18. Hu F, Ren J, Zhang JE, Zhong W, Luo M. 2012. Natriuretic peptides block synaptic transmission by activating phosphodiesterase 2A and reducing presynaptic PKA activity. Proc Natl Acad Sci USA 109:17681-17686.
19. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE, Mullins D, Hyde LA, Eschle BK, Turnbull Z, Sloan H, Guzzi M, Zhang X, Wang A, Rindgen D, Mazzola R, Vivian JA, Eddins D, Uslaner JM, Bednar R, Gambone C, Le-Mair W, Marino MJ, Sachs N, Xu G, Parmentier-Batteur S. 2011. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo[3, 4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 61:665-676.
20. Khodosevich K, Jacobi E, Farrow P, Schulmann A, Rusu A, Zhang L, Sprengel R, Monyer H, von Engelhardt J. 2014. Coexpressed auxiliary subunits exhibit distinct modulatory profiles on AMPA receptor function. Neuron 83:601-615.
21. Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, Grimwood S, Guanowsky V, Hajós M, Harms JF, Helal CJ, Hoffmann WE, Kocan GP, Majchrzak MJ, McGinnis D, McLean S, Menniti FS, Nelson F, Roof R, Schmidt AW, Seymour PA, Stephenson DT, Tingley FD, Vanase-Frawley M, Verhoest PR, Schmidt CJ. 2012. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther 341:396-409.
22. Kroker KS, Rosenbrock H, Rast G. 2011. A multi-slice recording system for stable late phase hippocampal long-term potentiation experiments. J Neurosci Methods 194:394-401.
23. Kroker KS, Rast G, Giovannini R, Marti A, Dorner-Ciossek C, Rosenbrock H. 2012. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 62:1964-1974.
24. Kroker KS, Mathis C, Marti A, Cassel JC, Rosenbrock H, Dorner-Ciossek C. 2014. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging 35:2072-2078.
25. Lakics V, Karran EH, Boess FG. 2010. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367-374.
26. Lange-Asschenfeldt C, Schipke CG, Riepe MW. 2007. Multimodal gain control at the hippocampal Schaffer collateral-CA1 synapse. Neurosci Lett 416:101-105.
27. Lin DT, Fretier P, Jiang C, Vincent SR. 2010. Nitric oxide signaling via cGMP-stimulated phosphodiesterase in striatal neurons. Synapse 64:460-466.
28. Lu YF, Kandel ER, Hawkins RD. 1999. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 19:10250-10261.
29. Luebke JI, Dunlap K, Turner TJ. 1993. Multiple calcium channel types control glutamatergic synaptic transmission in the hippocampus. Neuron 11:895-902.
30. Lupica CR, Proctor WR, Dunwiddie TV. 1992. Presynaptic inhibition of excitatory synaptic transmission by adenosine in rat hippocampus: analysis of unitary EPSP variance measured by whole-cell recording. J Neurosci 12:3753-3764.
31. Manabe T, Wyllie DJ, Perkel DJ, Nicoll RA. 1993. Modulation of synaptic transmission and long-term potentiation: Effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J Neurophysiol 70:1451-1459.
32. Manita S, Suzuki T, Inoue M, Kudo Y, Miyakawa H. 2007. Paired-pulse ratio of synaptically induced transporter currents at hippocampal CA1 synapses is not related to release probability. Brain Res 1154:71-79.
33. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, Beavo JA. 2002. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci U S A 99:13260-13265.
34. Menniti FS, Faraci WS, Schmidt CJ. 2006. Phosphodiesterases in the CNS: Targets for drug development. Nat Rev Drug Discov 5:660-670.
35. Nathan T, Lambert JD. 1991. Depression of the fast IPSP underlies paired-pulse facilitation in area CA1 of the rat hippocampus. J Neurophysiol 66:1704-1715.
36. Nikolaev VO, Gambaryan S, Engelhardt S, Walter U, Lohse MJ. 2005. Real-time monitoring of the PDE2 activity of live cells. J Biol Chem 280:1716-1719.
37. Papatheodoropoulos C, Kostopoulos G. 2000. Dorsal-ventral differentiation of short-term synaptic plasticity in rat CA1 hippocampal region. Neurosci Lett 286:57-60.
38. Petersen RP, Moradpour F, Eadie BD, Shin JD, Kannangara TS, Delaney KR, Christie BR. 2013. Electrophysiological identification of medial and lateral performant path inputs to the dentate gyrus. Neuroscience 252:154-168.
39. Polito M, Klarenbeek J, Jalink K, Paupardin-Tritsch D, Vincent P, Castro LR. 2013. The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons. Front Cell Neurosci 7:211.
40. Regehr WG. 2012. Short-term presynaptic plasticity. Cold Spring Harb Perspect Biol 4:a005702.
41. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. 2009. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology 202:419-443.
42. Reneerkens OA, Rutten K, Bollen E, Hage T, Blokland A, Steinbusch HW, Prickaerts J. 2013. Inhibition of phosphodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res 236:16-22.
43. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K, Loughney K. 1997. Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3', 5'-cyclic nucleotide phosphodiesterase. Gene 191:89-95.
44. Rozov A, Burnashev N. 1999. Polyamine-dependent facilitation of postsynaptic AMPA receptors counteracts paired-pulse depression. Nature 401:594-598.
45. Rozov A, Jerecic J, Sakmann B, Burnashev N. 2001. AMPA receptor channels with long-lasting desensitization in bipolar interneurons contribute to synaptic depression in a novel feedback circuit in layer 2/3 of rat neocortex. J Neurosci 21:8062-8071.
46. Russwurm C, Zoidl G, Koesling D, Russwurm M. 2009. Dual acylation of PDE2A splice variant 3: Targeting to synaptic membranes. J Biol Chem 284:25782-25790.
47. Sanderson TM, Sher E. 2013. The role of phosphodiesterases in hippocampal synaptic plasticity. Neuropharmacology 74:86-95.
48. Schulz PE, Cook EP, Johnston D. 1994. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J Neurosci 14:5325-5337.
49. Sebastião AM, Ribeiro JA. 2009. Adenosine receptors and the central nervous system. Handb Exp Pharmacol 193:471-534.
50. Shinnick-Gallagher P, McKernan MG, Xie J, Zinebi F. 2003. L-type voltage-gated calcium channels are involved in the in vivo and in vitro expression of fear conditioning. Ann N Y Acad Sci 985:135-149.
51. Sierksma AS, Rutten K, Sydlik S, Rostamian S, Steinbusch HW, van den Hove DL, Prickaerts J. 2013. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacology 64:124-136.
52. Skov J, Andreasen M, Hablitz JJ, Nedergaard S. 2011. Baclofen and adenosine inhibition of synaptic transmission at CA3-CA1 synapses display differential sensitivity to K+ channel blockade. Cell Mol Neurobiol 31:587-596.
53. Son H, Lu YF, Zhuo M, Arancio O, Kandel ER Hawkins RD., 1998. The specific role of cGMP in hippocampal LTP. Learn Mem 5:231-245.
54. Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, O'Neill SM, Schmidt CJ, Weinberg RJ, Menniti FS. 2012. The distribution of phosphodiesterase 2A in the rat brain. Neuroscience 226:145-155.
55. Stroop SD, Beavo JA. 1991. Structure and function studies of the cGMP-stimulated phosphodiesterase. J Biol Chem 266:23802-23809.
56. van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Reymann KG, Schröder UH, Hendrix M. 2008. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 55:908-918.
57. van Staveren WC, Glick J, Markerink-van Ittersum M, Shimizu M, Beavo JA, Steinbusch HW de Vente J. 2002. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol 31:729-741.
58. van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J. 2003. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467:566-580.
59. Wang S, Hu P, Wang HL, Chen JT, Tang JL, Ruan DY. 2008. Effects of Cd(2+) on AMPA receptor-mediated synaptic transmission in rat hippocampal CA1 area. Toxicol Lett 176:215-222.
60. Wu LG, Saggau P. 1994. Presynaptic calcium is increased during normal synaptic transmission and paired-pulse facilitation, but not in long-term potentiation in area CA1 of hippocampus. J Neurosci 14:645-654.
61. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M. 2005. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68:1775-1781.
62. Yang Y, Xiong GJ, Yu DF, Cao J, Wang LP, Xu L, Mao RR. 2012. Acute low-dose melamine affects hippocampal synaptic plasticity and behaviour in rats. Toxicol Lett 214:63-68.